Present and future of new systemic therapies for early and intermediate stages of hepatocellular carcinoma

doi:10.3748/wjg.v30.i19.2512

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 30, Issue 19

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (906)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-2) series, Tables (1-1) series.

Item

Count

PDF

HTML

703

Figures (1-2)

Tables (1-1)

Sum=803

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=53

May 21, 2024 (publication date) through Jun 16, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Gastroenterol. May 21, 2024; 30(19): 2512-2522
Published online May 21, 2024. doi: 10.3748/wjg.v30.i19.2512

Present and future of new systemic therapies for early and intermediate stages of hepatocellular carcinoma

Juan Jose Urquijo-Ponce, Carlos Alventosa-Mateu, Mercedes Latorre-Sánchez, Inmaculada Castelló-Miralles, Moisés Diago

Juan Jose Urquijo-Ponce, Carlos Alventosa-Mateu, Mercedes Latorre-Sánchez, Inmaculada Castelló-Miralles, Moisés Diago, Hepatology Unit, Department of Digestive Diseases, Consorcio Hospital General Universitario of Valencia, Valencia 46014, Spain

Author contributions: Urquijo-Ponce JJ and Alventosa-Mateu C have equally contributed to the preparation of the manuscript; Urquijo-Ponce JJ designed the review, collected and analyzed the data and wrote the manuscript; Alventosa-Mateu C designed the review, collected and analyzed the data, elaborated the figures and tables and wrote the manuscript; Latorre-Sánchez M, Castelló-Miralles I and Diago M reviewed and revised the manuscript; All authors have read and approved the final manuscript.

Conflict-of-interest statement: Juan Jose Urquijo-Ponce and Moisés Diago have been paid for serving as a speaker and consultant for Roche. The remaining authors disclose no conflicts of interest to declare regarding the topics covered in this manuscript.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Carlos Alventosa-Mateu, MD, PhD, Doctor, Hepatology Unit, Department of Digestive Diseases, Consorcio Hospital General Universitario of Valencia, Av Tres Cruces 2, Valencia 46014, Spain. almacar84@hotmail.com

Received: February 22, 2024
Revised: April 8, 2024
Accepted: April 26, 2024
Published online: May 21, 2024

Core Tip

Core Tip: This review provides an updated analysis (up to March 2024) of the current data about the new systemic therapies for the hepatocellular carcinoma (HCC) in the early and intermediate stages; specially focusing on the findings of neoadjuvant and adjuvant systemic therapies after a treatment with curative intent, for prevention of HCC recurrence. Finally, we discuss about the potential benefits of these new systemic therapies for early and intermediate stages of HCC and their future impact in the HCC treatment schedules.